1. The use of a non-fucosylated anti-CD20 antibody with a fucose amount of 60% or less of the total amount of oligosaccharides (sugars) in the Asn297 position for the manufacture of a medicament for the treatment of cancer in combination with bendamustine. 2. The use according to claim 1, characterized in that the amount of fucose is from 40 to 60%. The use according to claim 1, characterized in that the amount of fucose is 50% or less. The use according to one of claims 1 to 3, characterized in that said cancer is a cancer expressing CD20.5. The use according to claim 4, characterized in that said cancer expressing CD20 is B-cell non-Hodgkin lymphoma (NHL) .6. The use according to one of claims 1 to 3, characterized in that said non-fucosylated anti-CD20 antibody is type II anti-CD20 antibody. The use according to claim 6, characterized in that said antibody is a humanized B-Ly1.8 antibody. The use according to one of claims 1 to 3, characterized in that one or more additional other cytotoxic, chemotherapeutic or anticancer agents or compounds are administered, or ionizing radiation is used, which enhances the effect of such agents. The use according to one of claims 1 to 3, characterized in that said humanized B-Ly1 antibody is administered at a dose of 800-1200 mg on days 1, 8, 15 of a 6-week dosing cycle and then at a dose of 800 to 1200 mg per 1 day of a 4-week cycle, which can last up to 5 times, and bendamustine is administered in a dose of 80 mg / md to 110 mg / mn 1 and 2 days of a 4-week cycle, which can last up to 6 times. 10. A composition comprising a non-fucosylated anti-CD20 antibody with a fucose amount of 60% or less of the total amount of oligosaccharides (sugars) as1. Применение нефукозилированного анти-CD20 антитела с количеством фукозы 60% или менее от общего количества олигосахаридов (сахаров) в положении Asn297 для получения лекарственного средства для лечения рака в комбинации с бендамустином.2. Применение по п.1, отличающееся тем, что количе
